Clinical study on the effect of cheek acupuncture combined with tropisetron on the prevention of nausea and vomiting after gynecological laparoscopic surgery

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300071833

Enrollment

Unknown

Registered

2023-05-26

Start date

2023-06-01

Completion date

Unknown

Last updated

2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative nausea and vomiting(PONV)

Interventions

Experimental group:Cheek acupuncture combined with tropisetron

Control group:Tropisetron

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Scheduled for elective laparoscopic gynecological surgery under general anesthesia. 2. Age ranging from 18 to 65 years at the time of enrollment. 3. Body Mass Index (BMI) within the range of 18.5 to 25 kg/m2. 4. Classified as American Society of Anesthesiologists (ASA) Physical Status Class I or II. 5. Demonstrated understanding of the clinical trial, as evidenced by voluntary participation of informed consent after a detailed explanation of the trial protocol before surgery.

Exclusion criteria

Exclusion criteria: 1. Received antiemetic therapy due to nausea or vomiting within 24 hours prior to surgery. 2. Received hormones or opioids within 24 hours before surgery. 3. Converted to laparotomy intraoperatively or applied self-controlled intravenous analgesia pump postoperatively 4. Currently undergoing chemotherapy treatments. 5. Pregnant or lactating at the time of enrollment. 6. Diagnosed with severe liver, kidney, or cardiopulmonary dysfunctions and severe gastrointestinal diseases within the last 6 months. 7. History of severe adverse events following administration of tropisetron hydrochloride. 8. Presence of skin infection or ulceration at designated acupuncture points. 9. Abnormal coagulation function as evidenced by laboratory tests. 10. Diagnosed with mental or communication disorders, or has taken psychotropic medications within the last 6 months.

Design outcomes

Primary

Measure	Time frame
Incidence of PONV;	—

Secondary

Measure	Time frame
Severity of PONV;Basal heart rate variabilities;Heart rate variabilities;Heart rate variabilities;Heart rate variabilities;Postoperative analgesics and antiemetic rescue;Exhaustion (Y/N) ;Adverse events related to antiemetic measures ;	—

Countries

China

Contacts

Public ContactBao Naren

First Affiliated Hospital of China Medical University

bnrlzh@sina.com+86 138 4202 1591

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026